Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...

本文研究中，研究人员定义了驱动尿路上皮癌进化的基本机制并阐明了其背后的重要治疗性意义。 晚期尿路上皮癌是一种经常性的致死性疾病，其特点表现为遗传异质性较为显著。近日，一篇发表在国际杂志Nature上题为“The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution”的研究报告中，来自威尔康奈尔医学院等机构的科学家 ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...

A humanised monoclonal antibody, KEYTRUDA can enhance the immune system's potential to detect and combat tumour cells.

Researchers discovered that antiviral enzymes induce early mutations in bladder cancer, and standard chemotherapy causes ...

Adding immunotherapy to platinum chemotherapy can improve outcomes of urothelial carcinoma, but that may depend on the platinum agent used.

The study focused on urothelial carcinoma, the most common form of bladder cancer, and used advanced whole-genome sequencing ...

A study led by researchers at Weill Cornell Medicine and the New York Genome Center illuminates as never before how bladder cancer originates and ...

This is the first comprehensive immunohistochemical analysis of the expression of several class I HDAC proteins (1, 2 and 3) in urothelial carcinoma. In our study, we found all three isoforms in a ...

This is the first approved combination treatment for radically unresectable urothelial carcinoma in Japan to offer an alternative to platinum-containing chemotherapy, the current standard of care for ...

Patients with the mesenchymal-like subtype had both significantly lower response rate and shorter survival, while the luminal-like subtypes (urothelial-like and genomically unstable) displayed the ...